Treatment and outcome of Hodgkin lymphoma (HL) are the true success story of modern medicine. The data from the developing countries on long-term outcome of patients with HL is sparse.Aims:Primary objective is to assess the progression-free survival (PFS). Secondary objective are overall survival (OS) and toxicities.Settings and Design:This is a retrospective analysis from the case records from a single institution.Materials and Methods:Institutional Ethical Committee approval was obtained. Between January 1991 and December 2010, 301 patients (age ≥18 years) underwent treatment at our institution.Statistical Analysis:Kaplan–Meyer curves were used to calculate the PFS and OS.Results:The median age at presentation was 36 years, range from 19 to 75 years. The male to female ratio was 2.9:1. Seventy-five percent of patients had B symptoms. Majority presented in advanced stage (Stage III and IV) disease (64.7%). Mixed cellularity (74.4%) was the most common histology, followed by nodular sclerosis (13.9%). The most common chemotherapy regimen used was ABVD (61%).Conclusions:Median follow-up of the cohort was 18.5 months (range 2-225). PFS and OS rate at 5 years is 66.3% and 79.7% respectively.

No abstract

7061 Background: The use of imatinib (IM) now offers most patients with CML lengthy remissions and the hope of normal life expectancy. Majority of our CML patients are in the reproductive age group, and these improved survivals have resulted in issues relating to fertility and procreation. There is limited literature on the outcomes of pregnancy in women who continued IM during conception and through antenatal period. Methods: All women with CML who wished to conceive were counselled about the risks of pregnancy while on IM. They were given the choice of termination or stopping IM until delivery or continuing on IM with attendant risk to mother and baby. The records of all patients with CML treated with IM at our institute were retrospectively analysed over a period of 10 years. A total of 28 pregnancies in 25 women were documented. Only those women who were exposed to imatinib during conception and first trimester were included for this analysis. We report the outcome of 24 pregnancies in 22 women who had continued on IM in antenatal period. Results: Of the total of 24 pregnancies, 23 occurred in chronic phase and 1 in Blast phase. 21 of these conceptions occurred at IM dose of 400mg/ day, 1 at 600mg/ day and 2 at 800mg/ day. The median age at conception was 24.5 years (19-38). Mean time on IM at conception was 24.25 months (3-81). 19 patients (86.4%) were in CHR at conception and 11 of 22 patients (50%) attained complete cytogenetic response. The mean exposure to IM during pregnancy was 18.08 weeks (6-39 weeks).After explaining the pros and cons of continuation of pregnancy 6 women had stopped IM and 7 patients opted for termination of pregnancy. Conclusions: IM at higher dose appears to increase the risk of fetal loss. IM at standard dose of 400 mg does not appear to increase the incidence of congenital malformations or worsen foetal outcome. [Table: see text]

e18545 Background: Outside the setting of the clinical trials there is very little data of CHOP chemotherapy plus Rituximab (CHOP-R) compared with standard CHOP in Indian population. We analyzed our cohort of patients diagnosed with Diffuse Large B cell Lymphoma (DLBCL). Primary objective was to compare CHOP with CHOP-R in term of PFS and OS. Methods: All the patients aged more than 21 years diagnosed with DLBCL (CD 20+) were retrospectively analyzed from Jan 2000 to June 2011. According to institute guideline staging and International Prognostic Index (IPI) risk grouping were done. Patients were started on standard cyclophoshomide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.5mg/m2 on day 1 and prednisolone 60mg/m2 day 1-5 (CHOP). Rituximab 375 mg/m2 was given on day 1 depending on the affordability/Insurance. Clinical evaluation was done after each cycle and response assessment with CT scan was done after third and sixth cycle. Progression free survival (PFS) was defined as progression during therapy, relapse, death and lost to follow up. Overall survival was defined as time till death and lost to follow up. Statistical analysis was done using Graph pad software and p value less than 0.05 was taken significant. Results: There were 67 patients in CHOP-R and 206 patients in CHOP arm. Basic characteristics and survival data are described in table 1, which are not distributed equally in two arms. The PFS in R-CHOP and CHOP arms were 40 and 9 months respectively (p=0.0008). The OS in R-CHOP and CHOP arms were 47 and 13 months respectively (p=0.007). Conclusions: There was statistical difference between the PFS and OS between the two arms. [Table: see text]

e19533 Background: B Non Hodgkin Lymphoma (B-NHL) constitutes 90% of all NHLs. Surface CD20 is expressed in most of them. Standard of care worldwide for B NHLs currently is rituximab-based chemotherapy. In the present era, still rituximab-based chemotherapy is seldom used in India. We tried to analyze the proportion of eligible patients who received rituximab during their first line treatment and their outcome. Methods: We retrospectively analyzed all the cases of NHL patients registered at our center from 2001 to 2010. We defined “Refusal to treatment” as rejection of any therapeutic intervention, “abandonment” if treatment was initiated but not completed, “lost to follow up” as patients who have completed treatment, but missed the subsequent appointments. Results: A total of 1,351 cases of NHLs were registered during 2001-2010. B-NHLs constituted 90.6%. DLBCL accounted for 78.2% of all B-NHLs followed by follicular lymphoma (14.6%). Out of the 1,216 B-NHL patients registered, less than a third (377/1216 i.e 31%) were started on treatment, rest (69%) refused treatment. Four-fifths (79.3%) of the patients could complete at least 4 cycles of the intended chemotherapy, whereas 20.7% of them abandoned treatment in between. Rituximab-based chemotherapy could be initiated in only a quarter (94/377, 24.9%) of the eligible patients, out of which 68% (65/94) completed at least 4 cycles. Chemotherapy without rituximab was initiated in the remaining 75.1% of the patients, of which 78%(221/283) could complete at least 4 cycles. Among the 65 patients who completed at least 4 cycles of rituximab-based chemotherapy, 52% (34/65) were still alive without any evidence of disease as compared to 19% (42/221) of the patients who received chemotherapy without Rituximab at a median follow up of 17 months (range 1-125 months) p<0.05. The proportion of patients who were lost to follow up with evidence of disease at their last visit in the clinic was 4%(3/65) vs. 39%(86/221), in the rituximab vs. non-rituximab-containing chemotherapy groups respectively. Conclusions: Only 7.7% (94/1216) of the eligible B-NHL patients were able to receive rituximab-based chemotherapy. A distinct survival advantage is noted in patients who received rituximab.